Europe Viscosupplementation Market Size & Outlook
Europe viscosupplementation market, 2018-2030 (US$M)
Related Markets
Europe viscosupplementation market highlights
- The Europe viscosupplementation market generated a revenue of USD 630.6 million in 2023.
- The market is expected to grow at a CAGR of 10.7% from 2024 to 2030.
- In terms of segment, three injection was the largest revenue generating product in 2023.
- Single Injection is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, France is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 630.6 million |
| Market revenue in 2030 | USD 1,284.7 million |
| Growth rate | 10.7% (CAGR from 2023 to 2030) |
| Largest segment | Three injection |
| Fastest growing segment | Single Injection |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single Injection, Three Injection, Five Injection |
| Key market players worldwide | DePuy Synthes, Sanofi SA, Smith & Nephew PLC, Anika Therapeutics Inc, Zimmer Biomet Holdings Inc, Ferring, Lifecore Biomedical Inc, LG Chem, Roche Holding AG |
Other key industry trends
- In terms of revenue, Europe region accounted for 13.1% of the global viscosupplementation market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 1,284.7 million by 2030.
Three injection was the largest segment with a revenue share of 42.96% in 2023. Horizon Databook has segmented the Europe viscosupplementation market based on single injection, three injection, five injection covering the revenue growth of each sub-segment from 2018 to 2030.
The region witnessed a slight slowdown in market growth, owing to ongoing economic turmoil and growing competition in the market. However, it is anticipated that with the introduction of single injection treatments, the market is likely to recover. It is expected that the European viscosupplement market will witness a significant shift from multiple-injection cycle products to single-injection treatment, owing to greater convenience of the latter.
Europe regulatory system is comparatively less stringent for hyaluronic acid products than the U.S. In June 2016, Anika Therapeutics, Inc. launched CINGAL in Europe. The company intended to make the product available in Germany, Poland, Italy, Czech Republic, and Hungary. The product received CE mark in March 2016.
Large number of clinical trials are being conducted to provide efficient treatment for knee osteoarthritis with the help of stem cells. The European Union´s Horizon 2020 research funding program has provided approximately USD 6.5 million to the ADIPOA-2 project and includes 18 partners from Germany, Italy, France, the Netherlands, Ireland, and the UK.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viscosupplementation Market Scope
Viscosupplementation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe viscosupplementation market size, by country, 2018-2030 (US$M)
Europe Viscosupplementation Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
